PubMed Health⌕ Search

Biomedical subjects

T T Oei

Publications and source records attributed to T T Oei.

5 recordsLinked to original sources
PubMed1978

Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva.

The concentration-time curves of carbamazepine (CBZ) and its metabolite (carbamazepine-10,11-epoxide; CBZ-epoxide) were determined in patients undergoing long-term antiepileptic drug treatment with the use of plasma and saliva data. Plasma and saliva samples were assayed concurrently for each patient by liquid chromatography. There was excellent linear correlation between CBZ levels in saliva and plasma (r = 0.991, p less than 0.001) over a large concentration range. The saliva/plasma ratio for CBZ concentration was 0.26 +/- 0.01 (SD). Since CBZ binding to plasma proteins is in the order of 76%, saliva CBZ concentration seems to reflect the unbound fraction of the drug in plasma. CBZ-epoxide has not been detected in saliva. The pharmacokinetic parameters of CBZ-epoxide were determined in 6 patients. The pharmacokinetic parameters of CBZ obtained from saliva concentrations were in excellent agreement with those obtained from plasma concentrations. Thus, CBZ determination in saliva is convenient for controlling blood levels in patients as well as for studying pharmacokinetics. The half-life, the relative body clearance of CBZ, and the metabolite concentration during steady-state, expressed as percent the parent compound, appear to be significantly different in patients on single and combined drug therapy.

Adolescent↗
PubMed1977

Relationship between carbamazepine concentrations in plasma and saliva in man as determined by liquid chromatography.

The concentration of carbamazepine in plasma and saliva was determined in 7 subjects receiving carbamazepine. Plasma and saliva samples were assayed was an excellent linear relationship between carbamazepine concentrations in saliva and plasma (r = 0.991, p less than 0.001) over a plasma concentration range of 0.2--8.0 microgram/ml. The saliva/plasma ratio for carbamazepine was 0.26 +/- 0.02 (S.D.). Since carbamazepine binding to plasma proteins is in the order of 75%, the saliva concentration seems to reflect the concentration of the free drug in plasma. There is very little intrasubject and intersubject variation in the concentration ratio of carbamazepine. This study demonstrates that carbamazepine determination in saliva is a convenient method for optimizing blood levels of patients as well as for the study of pharmacokinetic properties.

Carbamazepine↗
PubMed1976

Safety and efficacy of prolonged treatment with Tremblex (dexetimide), an antiparkinsonian agent. A controlled study.

The trial involved 69 female, long-stay inpatients of the Voorburg mental hospital, of a median age of 50 years. Two groups were formed at the start of the trial. The first group (51 patients) on a maintenance therapy with orphenadrine, were now put on oral dexetimide. Individually adapted dosages ranged from 0.5 to 1.5 mg daily. The control group (18 patients) of antiparkinsonian agents did not take any in the course of the study either. After three and six months (end of trial) biochemical and haematologic parameters were assessed. Clinical evaluation of extrapyramidal symptoms was made in the dexetimide group. All patients of the control group and 47 of the dexetimide group completed the trial. Both groups were shown to be comparable with regard to all parameters. Statistical analysis showed significant improvement in dexetimide-patients with regard to gross motor tremor, facial inexpressiveness, parkinsonian gait (after two weeks) + dyskinesia (after six months).

Adult↗